Preclinical studies point to lithium ascorbate as a lithium alternative

Nine preclinical studies on public preprints suggest lithium ascorbate may offer lithium-like support with lower risk, but the findings are not peer reviewed and should not guide treatment. The work, from Normotim Research Group and funded by Normopharm, focuses on animal data, safety testing and enzyme targets tied to brain health.

Why it matters: - Lithium has been used for decades in psychiatry, including for bipolar disorder and major depression. - Conventional lithium can be hard to manage because of its narrow therapeutic range, kidney and thyroid risks, and the need for regular blood testing. - The new preclinical work is aimed at finding a lithium-based option that may work at lower doses with less toxicity. - The release says the research was funded by Normopharm.

What happened: - Normotim Research Group released nine preclinical studies as public preprints on Zenodo. - The manuscripts have not undergone formal journal peer review. - The release says the findings should not be used to guide treatment, dosing or substitution of prescribed lithium medication. - The studies focus on lithium ascorbate, an organic compound made from lithium and ascorbic acid, or vitamin C.

The details: - AI modeling ranked lithium ascorbate ahead of 1,245 possible organic lithium salts for its ability to inhibit key enzymes and receptors involved in brain health. - The compound stood out for blocking GSK-3β, a target linked to metabolism, brain signaling and neurotransmitters such as serotonin and noradrenaline. - Olga Gromova, chief scientific officer for Normotim, said GSK-3 is involved in glucose metabolism, brain function and neurotransmitter activity. - Further studies reported antidepressant, anti-anxiety and neurogenerational properties. - One paper, “Toxicity and Pharmacokinetics of Lithium Ascorbate,” examined absorption, distribution and safe dosage ranges. - That study found rapid absorption, broad tissue distribution and prolonged lithium retention in blood and frontal brain tissue. - A second paper, “Pharmacological Safety of Lithium Ascorbate,” evaluated cardiovascular, respiratory, central nervous system, allergic and reproductive-organ effects. - The studies found low-to-moderate preclinical toxicity and safety, which the release says supports further research. - All of the studies were conducted under Good Laboratory Practice standards for non-clinical safety research.

Between the lines: - The release frames lithium ascorbate as a potential workaround for the safety limits that constrain standard lithium use. - The AI-ranking result is an early screening step, not proof of clinical benefit in people. - The strongest claims in the release remain preclinical, so the practical relevance for patients is still unproven.

What's next: - The research team appears to be using the preprints to support more study of lithium ascorbate in larger and more advanced testing. - Any move toward clinical use would require human trials and regulatory review. - The release directs readers to the preprints on Zenodo and includes a Wikipedia link for more information: Download the preprints and the second preprint.